125 related articles for article (PubMed ID: 34089986)
21. Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.
Kotraiah V; Pallares D; Toema D; Kong D; Beausoleil E
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):489-94. PubMed ID: 22380773
[TBL] [Abstract][Full Text] [Related]
22. UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells.
Wang Y; Wang CH; Zhang YF; Zhu L; Lei HM; Tang YB
Metabolomics; 2019 Mar; 15(4):52. PubMed ID: 30911937
[TBL] [Abstract][Full Text] [Related]
23. Insight into the Structural Requirements of Theophylline-Based Aldehyde Dehydrogenase lAl (ALDHlAl) Inhibitors Through Multi-QSAR Modeling and Molecular Docking Approaches.
Abdul Amin S; Adhikari N; Gayen S; Jha T
Curr Drug Discov Technol; 2016; 13(2):84-100. PubMed ID: 27132720
[TBL] [Abstract][Full Text] [Related]
24. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.
Yang Y; Zhou W; Xia J; Gu Z; Wendlandt E; Zhan X; Janz S; Tricot G; Zhan F
Oncotarget; 2014 Dec; 5(23):11986-97. PubMed ID: 25230277
[TBL] [Abstract][Full Text] [Related]
25. The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia.
Dancik GM; Varisli L; Vlahopoulos SA
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298333
[TBL] [Abstract][Full Text] [Related]
26. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
Sládek NE; Kollander R; Sreerama L; Kiang DT
Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
[TBL] [Abstract][Full Text] [Related]
27. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems.
Levi BP; Yilmaz OH; Duester G; Morrison SJ
Blood; 2009 Feb; 113(8):1670-80. PubMed ID: 18971422
[TBL] [Abstract][Full Text] [Related]
28. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
29. A High-Content Assay Enables the Automated Screening and Identification of Small Molecules with Specific ALDH1A1-Inhibitory Activity.
Yasgar A; Titus SA; Wang Y; Danchik C; Yang SM; Vasiliou V; Jadhav A; Maloney DJ; Simeonov A; Martinez NJ
PLoS One; 2017; 12(1):e0170937. PubMed ID: 28129349
[TBL] [Abstract][Full Text] [Related]
30. Distinct Connectivity and Functionality of Aldehyde Dehydrogenase 1a1-Positive Nigrostriatal Dopaminergic Neurons in Motor Learning.
Wu J; Kung J; Dong J; Chang L; Xie C; Habib A; Hawes S; Yang N; Chen V; Liu Z; Evans R; Liang B; Sun L; Ding J; Yu J; Saez-Atienzar S; Tang B; Khaliq Z; Lin DT; Le W; Cai H
Cell Rep; 2019 Jul; 28(5):1167-1181.e7. PubMed ID: 31365862
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen, an anticancer drug, is an activator of human aldehyde dehydrogenase 1A1.
Belmont-Díaz JA; Calleja-Castañeda LF; Yoval-Sánchez B; Rodríguez-Zavala JS
Proteins; 2015 Jan; 83(1):105-16. PubMed ID: 25354921
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sterzyſska K; Sosiſska P; Andrzejewska M; Zawierucha P; Nowicki M; Zabel M
Int J Biochem Cell Biol; 2016 Sep; 78():248-259. PubMed ID: 27443528
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Small-Molecule Activators for Glucose-6-Phosphate Dehydrogenase (G6PD) Using Machine Learning Approaches.
Saddala MS; Lennikov A; Huang H
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102234
[TBL] [Abstract][Full Text] [Related]
34. ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin.
Wang W; He S; Zhang R; Peng J; Guo D; Zhang J; Xiang B; Li L
Biomed Pharmacother; 2020 May; 125():109940. PubMed ID: 32044720
[TBL] [Abstract][Full Text] [Related]
35. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.
Sreerama L; Sládek NE
Cancer Chemother Pharmacol; 2001 Mar; 47(3):255-62. PubMed ID: 11320670
[TBL] [Abstract][Full Text] [Related]
36. Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.
Huddle BC; Grimley E; Buchman CD; Chtcherbinine M; Debnath B; Mehta P; Yang K; Morgan CA; Li S; Felton J; Sun D; Mehta G; Neamati N; Buckanovich RJ; Hurley TD; Larsen SD
J Med Chem; 2018 Oct; 61(19):8754-8773. PubMed ID: 30221940
[TBL] [Abstract][Full Text] [Related]
37. Flavonostilbenes natural hybrids from
Elsaman T; Ahmad I; Eltayib EM; Suliman Mohamed M; Yusuf O; Saeed M; Patel H; Mohamed MA
J Biomol Struct Dyn; 2024 Apr; 42(6):3249-3266. PubMed ID: 37261483
[TBL] [Abstract][Full Text] [Related]
38. Molecular cloning and baculovirus expression of the rabbit corneal aldehyde dehydrogenase (ALDH1A1) cDNA.
Manzer R; Qamar L; Estey T; Pappa A; Petersen DR; Vasiliou V
DNA Cell Biol; 2003 May; 22(5):329-38. PubMed ID: 12941160
[TBL] [Abstract][Full Text] [Related]
39. Investigating the Role of Missense SNPs on ALDH 1A1 mediated pharmacokinetic resistance to cyclophosphamide.
Verma H; Silakari O
Comput Biol Med; 2020 Oct; 125():103979. PubMed ID: 32877739
[TBL] [Abstract][Full Text] [Related]
40. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
Yao W; Wang L; Huang H; Li X; Wang P; Mi K; Cheng J; Liu H; Gu C; Huang L; Huang J
BMC Cancer; 2020 Apr; 20(1):315. PubMed ID: 32293355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
